Switzerland’s Roche flags U.S. plans after Trump pharma tariff announcement
NeutralFinancial Markets

Switzerland's Roche has indicated potential plans for the U.S. market following President Trump's announcement of new tariffs on pharmaceuticals. This development is significant as it could impact drug pricing and availability in the U.S., affecting both consumers and the pharmaceutical industry. Roche's response may shape its strategy in navigating the evolving regulatory landscape.
— Curated by the World Pulse Now AI Editorial System